4.5 Interaction with other medicinal products and other forms of interaction  
 No dedicated clinical drug interaction studies have been conducted. 
 Concomitant use of strong CYP3A4 inducer might lead to lower exposure of selinexor.  
 No clinically significant differences in selinexor pharmacokinetics were observed when co -administered wi th a strong CYP3A4 inhibitor, clarithromycin (500 mg PO twice daily for 7 days). 
 No clinically significant differences in selinexor pharmacokinetics were observed when co -administered with up to 1000 mg daily dose of paracetamol.  
